MONTREAL--(BUSINESS WIRE)--Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced that its most advanced product candidate, ANG1005, a novel paclitaxel-peptide drug conjugate in development for breast cancer patients with brain metastasis and patients with primary brain cancer, has been chosen as one of the Top 10 Oncology Projects to Watch by Elsevier Business Intelligence. Jean E. Lachowicz, Ph.D., Chief Scientific Officer of Angiochem, will provide a summary of ANG1005 during her presentation at the 2013 Therapeutic Area Partnerships conference being held November 18-20, 2013 at the Hyatt Regency, Boston. Dr. Lachowicz’s presentation will take place at 1:30 p.m. ET on Tuesday, November 19, 2013 during the Top 10 Oncology Projects to Watch session.
"We are delighted that ANG1005 has been selected as a Top 10 Project to Watch,” said Jean-Paul Castaigne, MD, CEO of Angiochem. “The ANG1005 program has advanced significantly over the past year. We initiated a Phase 2 clinical study in patients with recurrent high-grade glioma based on promising signs of anti-tumor activity observed in a Phase 1 study. In addition, we presented a complete analysis of a Phase 2 clinical study with ANG1005 in breast cancer patients with brain metastasis at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference. Based on these data that demonstrate encouraging response to ANG1005, we also plan to advance the molecule into further clinical development for breast cancer patients with brain metastasis in the near future.”
The Top Projects to Watch were chosen in each of six therapeutic areas by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. The criteria for selection include large market, large unmet medical need, increasing opportunity, history of the molecule/drug, strong science, strong company, diversity of indications, potential for new opportunities beyond initial indications and potential for multi-level partnering opportunities (biotech to biotech and biotech to pharma).
ANG1005 is a novel paclitaxel-peptide drug conjugate that represents the first oncology product to leverage the (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 has been studied in over 200 patients in three clinical studies; two phase 1 studies where the product has shown tolerability similar to paclitaxel and indications of activity, and a Phase 2 study for which the intent-to-treat (ITT) analysis demonstrated encouraging signs of anti-tumor activity and was reported at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference. A multi-study Phase 2 clinical program has been initiated to further confirm the clinical activity of ANG1005 observed in these earlier studies.
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.
Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.